About US
Contact us
-
Regeneron's Eylea beats out the competition in the U.S. as patient demand picks back upIn their battle for a larger piece of themacular degeneration pie, Regeneron's Eylea is edging outRoche's Lucentis in the key U.S. market. With sales of $1.35 billion in the first quarter, a 15% incr2021/5/10
-
An Alzheimer's med for $2,500? Watchdog blasts Biogen's aducanumab data, suggests low priceConflicting clinical results from Biogen and Eisai’s closely watched Alzheimer’s disease candidate aducanumab have already fueled plenty of controversies. Now aU.S. drug pricing watchdog has used tha2021/5/10
-
Moderna CEO says he's not losing any sleep over Biden's support for COVID-19 vaccine waiverModerna shares plummeted overnight alongside fellow COVID-19drugmakers after the Biden administration came out in favor of temporarily waiving intellectual property rights for their vaccines. But toM2021/5/8
-
Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campusSince purchasingcell and gene therapy CDMO MaSTherCell early last year, Catalent has been on an M&A tear in Belgium. With yet another deal, it’sbringing another local manufacturer—and a newfactor2021/5/8
-
Another 5 years of dominance: Oncology, immunology will extend their lead as pharma's top fields through 2025Cancer and autoimmune diseases aren’t going anywhere. And so the scramble to develop next-gen treatments rages on. As a result, global spending on oncology and immunology medicines will significantly2021/5/6
-
Fierce Pharma Asia—BeiGene touts Q1, PARP inhibitor nod; Astellas culls muscle disease pactBeiGene's first-quarter sales jumped 104% year over year to $106 million as it started to benefit from demand surgingon new national reimbursement coverage. The Chinese biotech also won a local go-ah2021/5/6
-
Gene therapy 'development engine' scores $120M to beef up contract manufacturingLess than a year after launch, gene therapy biotech-CDMO hybrid Forge Biologics has scored another round of investor cash to grow its viral vector ambitions. The self-styled gene therapy “development2021/4/30
-
Just how much COVID-19 vaccine money is on the table? A whopping $157B through 2025, report saysDrugmakers who seized the opportunity to develop vaccines against the coronavirus are on their way to reaping significant revenues. Exactly how much money is on the table? In its annual forecast for2021/4/30
-
Pfizer weighs sale of Philly-area campus—where 2,000 once worked—as company mulls when and how to bring employees backNot only do corporations have to determine when to bring employees back into the office after more than a year of at-home work, but how. It’s a decision even major COVID-19 drugmakers are evaluating2021/4/28
-
Johnson & Johnson scores in talc appeals as NJ court knocks down $117M verdictJohnson & Johnson has been hit with billions in talc verdicts, but it's had mixed successin appeals. With a new decision Wednesday, the company chalked up its latest appeals win. A court in J&2021/4/28